---
schema_version: "secwatch.filing_event.v1"
accession: "0001014739-22-000046"
form_type: "8-K"
ticker: "OPCH"
cik: "0001014739"
company_name: "Option Care Health, Inc."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-22T23:12:29.776621+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Option Care Health Q3 revenue up 14.5% to $1.02B; EPS $0.21; raises full-year guidance

## Summary
- Net revenue $1,020.9M, up 14.5% YoY; gross margin 21.4% vs 22.8% in Q3 2021.
- Net income $38.8M ($0.21 diluted EPS) vs $35.5M ($0.20) a year ago.
- Adjusted EBITDA $85.6M (8.4% of revenue), up 9.8% from $78.0M.
- FY2022 guidance: net revenue $3.90-3.95B, adj. EBITDA $336-341M, cash from ops ≥$250M.
- Acquired Rochester Home Infusion for $27.4M in cash; cash balance $255.5M.

## SEC filing metadata
- accession: 0001014739-22-000046
- form_type: 8-K
- ticker: OPCH
- cik: 0001014739
- company_name: Option Care Health, Inc.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1014739/000101473922000046/0001014739-22-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1014739/000101473922000046/bios-20221027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001014739-22-000046
- JSON: https://secwatch.observer/filing/0001014739-22-000046.json
- Plain text: https://secwatch.observer/filing/0001014739-22-000046.txt

## Key facts
- Earnings Releases
  Option Care Health, Inc. reported third quarter ended September 30, 2022 results: revenue $1,020.9 million, net income $38.8 million, or $0.21 per share, EPS $0.21 per share. Guidance raised.
  - Period: third quarter ended September 30, 2022
  - Revenue: $1,020.9 million
  - Net income: $38.8 million, or $0.21 per share
  - EPS: $0.21 per share
  - Guidance: raised
  - Result: reported results
  source text: and alternate site infusion services, today announced financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights • Net revenue of $1,020.9 million, up 14.5% compared to $891.9 million in the third quarter of 2021 • Gross profit of $218.0 million, or 21.4% of net revenue, up 7.4% compared to $203.0 million, or 22.8% of net
  evidence_url: https://www.sec.gov/Archives/edgar/data/1014739/000101473922000046/0001014739-22-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.